Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04902261
Other study ID # CHEC2020-144
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date November 20, 2020
Est. completion date November 20, 2023

Study information

Verified date August 2023
Source Changhai Hospital
Contact Shiwei Guo, Doctor
Phone +8618621500666
Email gestwa@163.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the efficacy of Tislelizumab combined with Nab-paclitaxel and Gemcitabine in the treatment of recurrent pancreatic cancer


Description:

There is heterogeneity in desmoplasia between different metastatic sites in pancreatic cancer. The tumor quasi-characteristics of patients with metastatic PDAC at presentation were more obvious than those of epithelial characteristics, and the quasi-and epithelial subtypes showed different responses to chemotherapy regimens, and the epithelial phenotype tumor quasi-phenotype was associated with metastasis-free survival. Therefore, different metastases of pancreatic cancer may respond differently to medical treatment. There were different metastases after postoperative recurrence of pancreatic cancer, 25.2% had only liver metastases, 14.7% had only lung metastases, 14.7% had multiple distant metastases, and about more than half of the patients had postoperative recurrence with only distant metastases and no in situ metastasis. Then whether there is a difference in the efficacy of PD1 drug therapy in patients with different metastases needs to be further verified.


Recruitment information / eligibility

Status Recruiting
Enrollment 140
Est. completion date November 20, 2023
Est. primary completion date November 20, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with radiologically or histologically confirmed postoperative Recurrent Pancreatic Cancer - Patients with at least one measurable lesion (according to RECIST 1.1 criteria); - Have not received gemcitabine-based regimen after surgery - No systemic treatment after diagnosis of recurrence - ECOG score 0-1 - Expected survival = 3 months; - Liver function is essentially normal: absolute neutrophil count > 1500/mm ³; platelet count > 100,000/mm ³; creatinine less than 1.5 times the upper limit of normal or calculated creatinine clearance (CRCI) > 45 mL/min; total bilirubin = 2.0 mg/dL; aspartate aminotransferase (AST) and alanine aminotransferase less than 2.5 times the upper limit of normal - Appropriate to participate in this trial as assessed by the investigator before entering the study - Male and female subjects of childbearing potential must agree to use an effective method of contraception throughout the study - Signed Informed Consent Form Exclusion Criteria: - Patients who only undergo abdominal laparotomy but do not undergo resection of pancreatic tumor tissue - Received gemcitabine-based regimen after surgery - Systemic treatment after diagnosis of recurrence - Patients with previous allergic reactions to similar drugs - Pregnant or lactating patients - Presence of pericardial effusion, uncontrolled pleural effusion, or clinically significant ascites at screening (including detectable ascites or ascites requiring puncture and aspiration on physical examination at screening) - History of interstitial lung disease, pneumonitis, or uncontrolled systemic disease, including diabetes, hypertension, pulmonary fibrosis, acute lung disease, etc - Patients with severe cardiovascular diseases within 12 months before enrollment, such as symptomatic coronary heart disease, = grade II congestive heart failure, uncontrolled arrhythmia, myocardial infarction, etc - Presence of any active immunodeficiency or autoimmune disease and/or history of any immunodeficiency or autoimmune disease that may recur at screening (e.g., hypothyroidism or hyperthyroidism, interstitial pneumonia, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, etc) - Use of steroids or other systemic immunosuppressive therapy 14 days prior to enrollment - Patients with other previous malignancies who are not cured - Immunodeficient patients, such as HIV-positive - Uncontrollable psychosis

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tislelizumab
Tislelizumab 200 mg every three weeks
Nab paclitaxel
Nab-paclitaxel 125mg/m2 on d1 and d8 every three weeks
Gemcitabine
Gemcitabine 1000mg/m2 on d1 and d8 every three weeks

Locations

Country Name City State
China Changhai Hospital Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Changhai Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary 1-Year Survival Rates The proportion of patients who survive more than 1 year after treatment. Up to 2 years
Secondary Overall Response Rate(ORR) the proportion of patients who had a best overall tumor response rating of complete response (CR) or partial response (PR) Up to 2 years
Secondary Progression Free Survival (PFS) The time from the date of treatment to the first of either disease progression, relapse or death Up to 2 years
Secondary Overall survival (OS) The time from the date of treatment start to the date of death or to the date of last follow-up for patients alive Up to 2 years
Secondary Adverse Events (AEs) the proportion of patients with AE, treatment-related AE (TRAE), immune-related AE (irAE), serious adverse event (SAE), assessed by NCI CTCAE v5.0; Surgical safety including Intraoperative blood loss,PHLF assessed by ISGLS(2012),Postoperative complications evaluated by modified Clavien-Dindo system. Up to 2 years
See also
  Status Clinical Trial Phase
Completed NCT01064622 - Gemcitabine Hydrochloride With or Without Vismodegib in Treating Patients With Recurrent or Metastatic Pancreatic Cancer Phase 1/Phase 2
Completed NCT00095966 - Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Phase 2
Completed NCT01846520 - Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers N/A
Completed NCT01191684 - Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer Phase 1
Terminated NCT01233505 - Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors Phase 1
Completed NCT01232829 - Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer Phase 2
Completed NCT00735917 - Saracatinib in Treating Patients With Previously Treated Metastatic Pancreatic Cancer Phase 2
Completed NCT01222689 - Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Phase 2
Completed NCT00397787 - Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine Phase 2
Completed NCT00028496 - Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer Phase 1
Completed NCT02153450 - Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer Early Phase 1
Completed NCT01821612 - Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer Early Phase 1
Completed NCT00474812 - Dasatinib in Treating Patients With Metastatic Pancreatic Cancer Phase 2
Terminated NCT00087191 - EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer N/A
Completed NCT00063947 - Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer Phase 1
Completed NCT01537107 - Sirolimus and Vismodegib in Treating Patients With Solid Tumors or Pancreatic Cancer That is Metastatic or Cannot Be Removed By Surgery Phase 1
Completed NCT01806675 - 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Phase 1/Phase 2
Withdrawn NCT02048943 - Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer Phase 1
Completed NCT00577889 - Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer Phase 2
Completed NCT00462553 - Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors Phase 1